Last update 07 Jun 2025

PF-06936308

Overview

Basic Info

Drug Type
Therapeutic vaccine
Synonyms
Vaccine-based immunotherapy regimen-2, PF 06936308, VBIR-2
Target
CTLA4 x PD-1
Action
inhibitors
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Therapeutic Areas
NeoplasmsRespiratory DiseasesSkin and Musculoskeletal Diseases
Active Indication-
Inactive Indication
Advanced Lung Non-Small Cell CarcinomaMetastatic Triple-Negative Breast Carcinoma
Originator Organization
Pfizer Inc.Pfizer Inc.
Active Organization-
Inactive Organization
Pfizer Inc.Pfizer Inc.
License Organization-
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with PF-06936308
NCT03674827
/ TerminatedPhase 1
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFICATION OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN-2 (VBIR-2) (PF-06936308) FOR ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC TRIPLE-NEGATIVE BREAST CANCER
100 Clinical Results associated with PF-06936308
Login to view more data
100 Translational Medicine associated with PF-06936308
Login to view more data
100 Patents (Medical) associated with PF-06936308
Login to view more data
100 Deals associated with PF-06936308
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 1
United States
Pfizer Inc.Pfizer Inc.
27 Nov 2018
Metastatic Triple-Negative Breast CarcinomaPhase 1
United States
Pfizer Inc.Pfizer Inc.
27 Nov 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03674827 (CTgov)
Phase 1
Advanced Lung Non-Small Cell Carcinoma | Metastatic Triple-Negative Breast Carcinoma
36
Adenovirus C68 (AdC68)
(Cohort 1A Adenovirus C68 (AdC68) 2X10^11 Viral Particles (VP) + Plasmid DNA (pDNA) 5 mg)
xtnmmhdqge = vozplkzxag qpvkxcnejn (quhlijpvtr, qkimajihhy - sgmxsxghng)
View more
-
23 Aug 2024
pDNA
(Cohort 2A AdC68 6X10^11 VP + pDNA 5 mg)
xtnmmhdqge = octjefrpjy qpvkxcnejn (quhlijpvtr, rfjjaferfs - helpzmohll)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free